Disulfiram, a Re-positioned Aldehyde Dehydrogenase Inhibitor, Enhances Radiosensitivity of Human Glioblastoma Cells In Vitro
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Glioblastoma, the most common brain tumor in adults, has poor prognosis. The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect. Materials and Methods Five human glioblastoma cells (U138MG, T98G, U251MG, U87MG, and U373MG) and one normal human astrocyte (NHA) cell were cultured and treated with DSF or 6MV X-rays (0, 2, 4, 6, and 8 Gy). For combined treatment, cells were treated with DSF before irradiation. Surviving fractions fit from cell survival based on colony forming ability. Apoptosis, DNA damage repair, and cell cycle distribution were assayed by western blot for cleaved caspase-3, H2AX staining, and flow cytometry, respectively. Results DSF induced radiosensitization in most of the glioblastoma cells, especially, in the cells with radioresistance as wildtype unmethylated promoter (MGMT-wt), but did not in normal NHA cell. DSF augmented or induced cleavage of caspase-3 in all cells after irradiation. DSF inhibited repair of radiation-induced DNA damage in MGMT-wt cells, but not in cells with methylated MGMT promoter. DSF abrogated radiation-induced G2/M arrest in T98G and U251MG cells. Conclusion Radiosensitivity of glioblastoma cells were preferentially enhanced by pre-irradiation DSF treatment compared to normal cell, especially radioresistant cells such as MGMT-wt cells. Induction of apoptosis or inhibition of DNA damage repair may underlie DSF-induced radiosensitization. Clinical benefit of combining DSF with radiotherapy should be investigated in the future.
Abstract
Purpose Glioblastoma, the most common brain tumor in adults, has poor prognosis. The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect. Materials and Methods Five human glioblastoma cells (U138MG, T98G, U251MG, U87MG, and U373MG) and one normal human astrocyte (NHA) cell were cultured and treated with DSF or 6MV X-rays (0, 2, 4, 6, and 8 Gy). For combined treatment, cells were treated with DSF before irradiation. Surviving fractions fit from cell survival based on colony forming ability. Apoptosis, DNA damage repair, and cell cycle distribution were assayed by western blot for cleaved caspase-3, H2AX staining, and flow cytometry, respectively. Results DSF induced radiosensitization in most of the glioblastoma cells, especially, in the cells with radioresistance as wildtype unmethylated promoter (MGMT-wt), but did not in normal NHA cell. DSF augmented or induced cleavage of caspase-3 in all cells after irradiation. DSF inhibited repair of radiation-induced DNA damage in MGMT-wt cells, but not in cells with methylated MGMT promoter. DSF abrogated radiation-induced G2/M arrest in T98G and U251MG cells. Conclusion Radiosensitivity of glioblastoma cells were preferentially enhanced by pre-irradiation DSF treatment compared to normal cell, especially radioresistant cells such as MGMT-wt cells. Induction of apoptosis or inhibition of DNA damage repair may underlie DSF-induced radiosensitization. Clinical benefit of combining DSF with radiotherapy should be investigated in the future.
참고문헌 (30)
- Stupp R, "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial", Lancet Oncol, 10, pp.459~466 (2009)
- Mirimanoff RO, "Radiotherapy and temozolomide for newly diagnosed glioblastoma : recursive partitioning analysis of the EORTC 26981", 22981-NCIC CE3 phase III randomized trial, 2006, pp.24, 2563~2569
- Hegi ME, "MGMT gene silencing and benefit from temozolomide in glioblastoma", N Engl J Med, 352, pp.997~1003 (2005)
- Costello JF, "Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase(MGMT)gene correlates with MGMT expression in human glioma cells", J Biol Chem, 269, pp.17228~17237 (1994)
- Wee CW, "Novel recursive partitioning analysis classification for newly diagnosed glioblastoma : a multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status", Radiother Oncol, 123, pp.106~111 (2017)
- Chinot OL, "Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma", N Engl J Med, 370, pp.709~722 (2014)
- Gilbert MR, "A randomized trial of bevacizumab for newly diagnosed glioblastoma", N Engl J Med, 370, pp.699~708 (2014)
- Stupp R, "Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma : a randomized clinical trial", JAMA, 314, pp.2535~2543 (2015)
- Wright C, "Disulfiram treatment of alcoholism", Am J Med, 88, pp.647~655 (1990)
- Yang EJ, "Revisiting non-cancer drugs for cancer therapy", Curr Top Med Chem, 16, pp.2144~2155 (2016)
- Choi SA, "Disulfiram modulates stemness and metabolism of brain tumor initiating cells in atypical teratoid", rhabdoid tumors, 2015, pp.17, 810~821
- Kast RE, "CUSP9* treatment protocol for recurrent glioblastoma : aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide", Oncotarget, 5, pp.8052~8082 (2014)
- Paranjpe A, "Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase(MGMT)in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage", Carcinogenesis, 35, pp.692~702 (2014)
- Srivenugopal KS, "Posttranslational regulation of O(6)-methylguanine-DNA methyltransferase(MGMT)and new opportunities for treatment of brain cancers", Mini Rev Med Chem, 16, pp.455~464 (2016)
- Triscott J, "Disulfiram, a drug widely used to control alcoholism, sup-presses the self-renewal of glioblastoma and over-rides resistance to temozolomide", Oncotarget, 3, pp.1112~1123 (2012)
- Lee YE, "Repositioning disulfiram as a radiosensitizer against atypical teratoid", rhabdoid tumor, 2017, pp.19, 1079~1087
- Rae C, "The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells", J Nucl Med, 54, pp.953~960 (2013)
- Cong J, "A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram", Cancer Lett, 409, pp.9~19 (2017)
- 김진호, "Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization", Cancer Research and Treatment, 48(3), pp.1130~1140 (2016), 대한암학회
- Fowler JF, "The linear-quadratic formula and progress in fractionated radiotherapy", Br J Radiol, 62, pp.679~694 (1989)
- 김진호, "Sequence-Dependent Radiosensitization of Histone Deacetylase Inhibitors Trichostatin A and SK-7041", Cancer Research and Treatment, 45(4), pp.334~342 (2013), 대한암학회[DOI]
- Kim HJ, "DNMT(DNA methyltransferase)inhibitors radiosensitize human cancer cells by suppressing DNA repair activity", Radiat Oncol, 7, pp.39~ (2012)
- Wick W, "Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation", Neuro Oncol, 15, pp.1405~1412 (2013)
- Nabors LB, "Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter : results of the open-label, controlled, randomized phase II CORE study", Neuro Oncol, 17, pp.708~717 (2015)
- Kaina B, "Targeting O(6)-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy", Cell Mol Life Sci, 67, pp.3663~3681 (2010)
- Blumenthal DT, "A Phase III study of radiation therapy(RT)and O(6)-benzylguanine+BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma : Southwest Oncology Group(SWOG)study S0001", Int J Clin Oncol, 20, pp.650~658 (2015)
- Cvek B, "Nonprofit drugs as the salvation of the world's healthcare systems : the case of Antabuse(disulfiram)", Drug Discov Today, 17, pp.409~412 (2012)
- Kovic B, "Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme", J Clin Oncol, 33, pp.2296~2302 (2015)
- Bernard-Arnoux F, "The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma", Neuro Oncol, 18, pp.1129~1136 (2016)
- Huang J, "A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy", J Neurooncol, 128, pp.259~266 (2016)